dc.creator | Rizzo, Manfredi | |
dc.creator | Abate, Nicola | |
dc.creator | Chandalia, Manisha | |
dc.creator | Rizvi, Ali A. | |
dc.creator | Giglio, Rosaria V. | |
dc.creator | Nikolić, Dragana | |
dc.creator | Gammazza, Antonella Marino | |
dc.creator | Barbagallo, Ignazio | |
dc.creator | Isenović, Esma R. | |
dc.creator | Banach, Maciej | |
dc.creator | Montalto, Giuseppe | |
dc.creator | Volti, Giovanni Li | |
dc.date.accessioned | 2018-03-01T16:04:45Z | |
dc.date.available | 2018-03-01T16:04:45Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 0021-972X | |
dc.identifier.issn | 1945-7197 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/508 | |
dc.description.abstract | Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; meanage: 57 +/- 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 +/- 0.4 vs 7.5 +/- 0.4%, P LT .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 +/- 4.1 vs 13.6 +/- 7.3 pg/ml, P = .0007 and 0.36 +/- 0.06 vs 0.44 +/- 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 +/- 0.05 vs 0.04 +/- 0.07 pg/ml, P = .0487 and 7.7 +/- 7.7 vs 3.6 +/- 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism. | en |
dc.relation | NIH Clinical and Translational Science Award [UL1TR000071] | |
dc.rights | openAccess | en |
dc.source | Journal of Clinical Endocrinology and Metabolism | en |
dc.title | Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study | en |
dc.type | article | en |
dcterms.abstract | Банацх, Мациеј; Барбагалло, Игназио; Николић Драгана; Цхандалиа, Манисха; Aбате, Ницола; Исеновић Есма; Монталто, Гиусеппе; Волти, Гиованни Ли; Гиглио, Росариа В.; Риззо, Манфреди; Ризви, Aли A.; Гаммазза, Aнтонелла Марино; | |
dc.citation.volume | 100 | |
dc.citation.issue | 2 | |
dc.citation.spage | 603 | |
dc.citation.epage | 606 | |
dc.identifier.wos | 000353350900065 | |
dc.identifier.doi | 10.1210/jc.2014-2291 | |
dc.citation.rank | M21 | |
dc.identifier.pmid | 25393640 | |
dc.type.version | publishedVersion | |
dc.identifier.scopus | 2-s2.0-84922569481 | |
dc.identifier.fulltext | https://vinar.vin.bg.ac.rs//bitstream/id/13149/504.pdf | |